The 18th Meeting of the International Society of Amyloidosis was held in Heidelberg, Germany, from September 4-8. This meeting brought together experts as they discussed novel therapies, clinical trial updates, and the diagnosis and management of amyloidosis.
It was an absolute pleasure to talk with our friends from @VJHemOnc about the non-for-profit AI solutions that we are developing to extend precise prognostication in MF and MDS to all healthcare systems. @ASH_hematology #GEMFIN @gesmd @_pethema @idis_research https://twitter.com/VJHemOnc/status/1621418665609412609
📣 Check out our latest weekly podcast, where you will hear from experts @mike_dickinson1 & Tycel Phillips (@LymphClinician), who share their highlights in NHL at #ASH22:
Each time I read an #AMLsm paper report morphological leukemia free state (MLFS) as a response criterion I cringe! While MLFS is listed in ELN criteria, it is not validated as proxy for long term benefit & does not reflect meaningful short term benefit to patients! Do you agree?
The 18th Meeting of the International Society of Amyloidosis
04–08 September 2022 | Heidelberg, Germany / Online
The 18th Meeting of the International Society of Amyloidosis was held in Heidelberg, Germany, from September 4-8. This meeting brought together experts as they discussed novel therapies, clinical trial updates, and the diagnosis and management of amyloidosis.
It was an absolute pleasure to talk with our friends from @VJHemOnc about the non-for-profit AI solutions that we are developing to extend precise prognostication in MF and MDS to all healthcare systems. @ASH_hematology #GEMFIN @gesmd @_pethema @idis_research https://twitter.com/VJHemOnc/status/1621418665609412609
📣 Check out our latest weekly podcast, where you will hear from experts @mike_dickinson1 & Tycel Phillips (@LymphClinician), who share their highlights in NHL at #ASH22:
Each time I read an #AMLsm paper report morphological leukemia free state (MLFS) as a response criterion I cringe! While MLFS is listed in ELN criteria, it is not validated as proxy for long term benefit & does not reflect meaningful short term benefit to patients! Do you agree?
Explore the latest updates in hematological stem cell transplantation, including expert interviews from major international congresses, podcasts and e-learning.